Endothelin Receptor Antagonists
-
Subject Areas on Research
- Addition of an endothelin receptor antagonist to modified Belzer's perfusion preservation solution mitigates the adverse effect of preretrieval warm ischemic injury on posttransplant glomerular filtration rate.
- Bosentan, an endothelin antagonist, augments hepatic graft function by reducing graft circulatory impairment following ischemia/reperfusion injury.
- Chronic thromboembolic pulmonary hypertension.
- Chronic thromboembolic pulmonary hypertension: detection, medical and surgical treatment approach, and current outcomes.
- Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis.
- Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
- Endothelin antagonism and contrast nephropathy.
- Endothelin receptor blockade during hypothermic perfusion preservation mitigates the adverse effect of preretrieval warm ischemic injury on posttransplant glomerular filtration rate.
- Endothelin-1 blockade corrects mesenteric hypoperfusion in a porcine low cardiac output model.
- Endothelin-receptor blockade mitigates the adverse effect of preretrieval warm ischemia on posttransplantation renal function in rats.
- Exacerbation of radiocontrast nephrotoxicity by endothelin receptor antagonism.
- Management of Pulmonary Arterial Hypertension in the Pediatric Patient.
- Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
- Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
- Tezosentan normalizes hepatomesenteric perfusion in a porcine model of cardiac tamponade.
- The combination of theophylline and endothelin receptor antagonism improves exercise performance of rats under simulated high altitude.
- Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial).